Skip to content

NAF announces selections for first round of Ataxia Centers of Excellence. LEARN MORE!

National Ataxia Foundation

2023 AAC

Case Study

A Continuous Effort Towards Treatment of SCA3

Written by Dr. Jorge Diogo Da Silva Edited by Dr. David Bushart How one research group assessed whether Rivastigmine, a Parkinson’s Disease drug, might have a role in treating SCA3 Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is the most common inherited ataxia worldwide. As with Read More…

Translate »
National Ataxia Foundation

Join NAF

Become a member for FREE!
It only takes a few moments.

Sign up today to receive:

  • News and research opportunities about your specific type of Ataxia as they become available
  • Early access to free webinars
  • eNewsletter and Generations publications